Table 6. Progression-free survival outcomes in studies including poor PS patients.
| Study | Patients | Poor PS, patients | mFU mo | mPFS, mo (95% CI) | Univariate, HR (95% CI); P value |
Multivariate, HR (95% CI); P value | ||
|---|---|---|---|---|---|---|---|---|
| Global population | PS 0-1 | Poor PS | ||||||
| Velcheti, Immunotherapy 2019 (31) | 402* | 103 PS 2* | 17 | NA | 6.5§ | 1.9§ | NA | NA |
| Tamiya, Invest New Drugs 2019 (32) | 213 | 32 PS=2; 9 PS=3; 1 PS=4 | 11 | 8.3 (6.0–10.7) | 9 (7.2–NA) | 4 (2.2–8.6) | 2.11 (1.37–3.27); P=0.000598 | 1.69 (1.05–2.72); P=0.03138 |
| Aguilar, Ann Oncol 2019 (33) | 187 | 34 PS≥2 | 12.6 | 6.5 (4.5–8.5) | NA | NA | 0.48 (0.30–0.76); P=0.002 | 0.47 (0.30–0.75); P=0.001 |
| Hasegawa, Anticancer Res 2019 (35) | 51 | 5 PS≥2 | 9.5 | 4.4 (1.9–8.4) | 5.3 (2.2–10.4) | 0.9 (0.5–NE) | 3.56 (1.35–9.38); P=0.010 | 3.889 (1.16–13.01); P=0.027 |
| Kuzminin, WCLC 2019 (36) | 74 | 9 PS=2 | 11 | 14.9 (6.14 –NR) | NR (NR–NR) | 2.5 (1.69–3.23) | 4.83 (2.03–11.20); P<0.001 | 3.28 (1.15–9.38); P=0.02 |
| Mielgo Rubio, ESMO 2019 (37) | 223 | 52 PS=2; 3 PS=3 | 6.8 | ±13 | NA | NA | 4.08 (2.52–6.69); P<0.001 | 3.24 (1.88–5.58); P<0.001 |
| Frost, ESMO 2019 (38) | 129 | 28 PS=2; 3 PS =3 | 13 | NA | 10.8 | 3.2 | 0.69 (0.43–1.12) | NA |
| Imai, J Cancer Res Clin Oncol 2020 (39) | 47 ≥75 y | 7 PS=2; 3 PS=3 | 10.1 | 7.0 (5.4–10.6) | 8.9 | 0.5 | 0.34 (0.16–0.77); P=0.01 | 0.47 (0.18–1.27); P=0.13 |
| Tambo, Clin Lung Cancer 2020 (41) | 95 | 11 PS=2; 10 PS=3/4 | 8.8 | 6.1 (3.64–8.56) | 7.9 | 3.4 | 2.15 (1.25–3.72); P=0.006 | 0.92 (0.46–1.85); P=0.817 |
| Amrane, Cancer Med 2020 (42) | 108 | 25 PS=2 | 8.2 | 10.1 (8.8–NR) | 10.4 (8.9–11.9) | 6.8 (5.0–8.6) | P=0.412 | NA |
| Facchinetti, Eur J Cancer 2020 (29) | 153 | 153 PS=2 | 18.2 | – | – | 2.4 (1.6–2.5) | NA | NA |
| Cortellini, Cancer Immun Immunother 2020 (28) | 1026 | 179 PS≥2 | 14.6 | 7.9 (6.9–9.5) | 10.4 (8.7–13.0) | 2.6 (1.9–3.30) | 2.65 (2.20–3.21); P<0.0001 | 2.48 (2.05–3.01); P<0.0001 |
| Cavaille, Tumori 2020 (43) | 41 | 6 PS=2; 5 PS=3 | 7.6 | 6 (3–NR) | NR (4–NR) | 2 (1–NR) | P<0.05 | NA |
| Alessi, J Immunother Cancer 2020 (44) | 234 | 39 PS=2 | NA | 6.2 (4.9–8.4) | 6.6 (5.23–10.36) | 4.0 (2.07–14.04) | 0.70 (0.47–1.06); P=0.091 | NA |
| Friedlaender, Acta Oncol 2020 (45) | 302 | 56 PS=2 | 8.6 | NA | 11.3 (8.5–14.4) | 2.6 (1.9–5.1) | P<0.001 | 3.0 (2.0 – 4.3) |
| Seban, Cancers (Basel) 2020 (46) | 63 | 13 PS≥2 | 13.4 | 7.7 (4.9–10.6) | NA | NA | 1.9 (0.9–4.0); P=0.09 | NA |
| Metro, J Immunother 2020 (48) | 282 | 49 PS=2; 3 PS=3 | 8.7 | 8.9 (5.9–12.0) | NA | NA | 2.93 (2.03–4.24); P<0.001# | 2.71 (1.85–3.97); P<0.001# |
| Kano, Cancer Sci 2020 (49) | 85 | 11 PS=2; 5 PS=3; 1 PS=4 | NA | NA | 8.1 (4.8–NR) | PS=2: 7.3 (1.5–11.4); PS=3–4: 1 (0.3–NR) |
PS 0–1 vs. 2 P=0.321 | NA |
| Yamaguchi, Sci Rep 2020 (50) | 48 | 18 PS=2/3 | 11.5 | 7.1 | 10.8 | 5.6 | 1.64 (0.77–3.40); P=0.18 | NA |
| Ichihara, Lung Cancer 2020 (51) | 84 | 18 PS≥2 | NA | 6.9 (3.8–11.4) | NA | NA | NA | 2.21 (1.15–4.28); P=0.017 |
| Sakai, J Cancer Res Clin Oncol 2020 (52) | 33 | 8 PS≥2 | 16.7 | NA | 0.47 (0.19–1.33); P=0.15 | 0.55 (0.22–1.56); P=0.25 | ||
*, patients with known negative status for sensitizing EGFR mutations and ALK fusions. §, “Real-word time on treatment” in the study. #, Time-to-treatment failure. y, years; PS, performance status; mFU, median follow-up; mo, months; NA, not available; mPFS, median progression-free survival; 95% CI, 95% confidence interval; NE, not estimable; NR, not reached; HR, hazard ratio.